Literature DB >> 1502483

Influence of smoking on basal and on vagally and maximally stimulated gastric acid and pepsin secretion.

A Lanas1, B I Hirschowitz.   

Abstract

Published data show that smokers have greater basal or peak acid and pepsin outputs, but the mechanisms underlying these effects are unknown. To confirm this and to determine whether these findings extend to, and implicate, any vagal overactivity, gastric secretions collected for 1 h basally, 1 h after 15 min of modified sham feeding (MSF), and 1 h after pentagastrin (6 micrograms/kg subcutaneously) were analyzed for acid and pepsin content in 204 subjects, 104 with duodenal ulcer (66 smokers) and 101 without (57 smokers). Maximal acid outputs (MAO, mu eq/kg/h, means +/- SEM) were higher in smokers than in non-smokers in both duodenal ulcer (DU) (623 +/- 35 versus 491 +/- 35, p less than 0.005) and non-DU (502 +/- 32 versus 376 +/- 20, p less than 0.005). Basal and MSF secretions were generally increased in smokers but, when expressed as a percentage of MAO, were not different in smokers and non-smokers (18% versus 17% and 43% versus 39%, respectively, in DU, and 13% versus 16% and 40% versus 36% in non-DU). Maximal pepsin outputs (units x 10(-2)/kg/h) were also higher in smokers than in non-smokers (DU, 129 +/- 7.9 versus 105 +/- 9.5, p = 0.05, and non-DU, 101 +/- 7.5 versus 77 +/- 10, p = 0.05). Basal and MSF secretions as a percentage of maximal pepsin output were not different in smokers versus non-smokers. Multivariate logistic regression shows that smoking was most strongly associated with MAO and sham feeding outputs, but the duration-intensity (pack-years) of smoking was associated only with elevated MAO.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1502483     DOI: 10.3109/00365529208999950

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

1.  Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori.

Authors:  M H Derakhshan; E El-Omar; K Oien; D Gillen; V Fyfe; J E Crabtree; K E L McColl
Journal:  J Clin Pathol       Date:  2006-04-27       Impact factor: 3.411

2.  Influence of smoking and Helicobacter pylori on gastric phospholipids.

Authors:  J Wenner; T Gunnarsson; H Graffner; G Lindell
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

3.  Gastric acid secretion and enteric infection in Bangladesh.

Authors:  C A Evans; R H Gilman; G H Rabbani; G Salazar; A Ali
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Nov-Dec       Impact factor: 2.184

4.  Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.

Authors:  E el-Omar; I Penman; C A Dorrian; J E Ardill; K E McColl
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

5.  Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of helicobacter pylori in duodenal ulcer patients. A controlled study.

Authors:  F Parente; G Maconi; O Sangaletti; M Minguzzi; L Vago; G Bianchi Porro
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

6.  A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.

Authors:  K E McColl; A M el-Nujumi; R S Chittajallu; S W Dahill; C A Dorrian; E el-Omar; I Penman; E J Fitzsimons; J Drain; H Graham
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

7.  Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.

Authors:  Kouichi Sakurai; Hiroko Suda; Yumi Ido; Takayuki Takeichi; Ayako Okuda; Kiwamu Hasuda; Masahiro Hattori
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

8.  A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer.

Authors:  Björn Lindkvist; Dorthe Johansen; Anders Borgström; Jonas Manjer
Journal:  BMC Cancer       Date:  2008-11-05       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.